You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The San Diego-based company is ramping up efforts to market its handheld molecular influenza test in anticipation of the upcoming flu season.
The portable, battery-operated system will be an interim solution for decentralized testing in places where power may be unreliable.
Formerly known as SlipChip Corp, the firm has recently won nearly $10 million in funding to hone its approaches to sepsis and CT/NG testing.
The observational study showed delays to diagnosis reduced the chances of identifying pathogens and generally led to poorer outcomes.
A project to use the host response to classify acute respiratory infections has been spun off into a company called Host Response, and is seeking industry partners.
The startup plans to launch research-use diagnostic tests this year and support customers wishing to build custom assays.
The firm showed 98 percent sensitivity and 100 percent specificity across all major HCV genotypes in a recent study.
The assay could provide detection of HBV infection at early stages, potentially preventing progression to cirrhosis or hepatocellular carcinoma.
Using an immunoassay as an initial screening tool saved approximately $36,000 over multiplex PCR panel use alone when performed in a period of high flu prevalence.
The technology will measure cancer-associated miRNAs using optical amplification with quantum dots and photonic crystals.
President Donald Trump announced the US would be leaving the World Health Organization, NBC News reports.
A study of Great Danes homes in on a genomic region linked to fearfulness.
CDC head says a new analysis indicates earlier testing wouldn't have caught viral spread, NPR reports.
In PLOS this week: gene expression and epigenetics of Indonesian populations, hookworm parasite secretome, and more.